U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. CDER Offices and Divisions
  6. Office of Immunology and Inflammation - Division of Gastroenterology (DG)
  1. CDER Offices and Divisions

Office of Immunology and Inflammation - Division of Gastroenterology (DG)


The Division of Gastroenterology (DG) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products intended for the prevention, treatment or diagnosis of gastrointestinal conditions including: 

  • Inflammatory bowel disease
  • Irritable bowel syndrome
  • Gastroesophageal reflux disease/erosive esophagitis
  • Duodenal/Gastric ulcers
  • Celiac disease
  • Eosinophilic gastrointestinal diseases
  • Motility disorders, including gastroparesis
  • Constipation
  • Bowel cleansing agents
  • Anorectal disorders
  • Anti-diarrheal agents
  • Anti-emetics (chemotherapy-induced or postoperative nausea and vomiting)
  • Short bowel syndrome
  • Pancreatic agents

Special Procedures for Physician Requests for Domperidone

Meetings and Workshops

Rare Diseases Information

Contact Us

Mailing Address: 

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Gastroenterology
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4177
Phone: (301) 796-2120
Fax: (301) 796-9838

Resources




Back to Top